Evidence map›Paper›PMID 21422743›Full record

ArticleProceedings of the Japan Academy. Series B, Physical and biological sciences2011

Procyanidins are potent inhibitors of LOX-1: a new player in the French Paradox.

Taichi Nishizuka, Yoshiko Fujita, Yuko Sato, Atushi Nakano, Akemi Kakino, Shunji Ohshima, Tomomasa Kanda, Ryo Yoshimoto, Tatsuya Sawamura

Erratum issuedOpen access · bronzeAbstract read
In one paragraph

Article in Proceedings of the Japan Academy. Series B, Physical and biological sciences, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 65 citations in OpenAlex.

  1. Review
  2. Protective Mechanism ofAntioxidants (Basel, Switzerland) · 2024
    Article
  3. Flavonoids inInternational journal of molecular sciences · 2023
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Taichi NishizukaDepartment of Vascular Physiology, National Cerebral and Cardiovascular Center, Osaka, Japan.
Yoshiko Fujita
Yuko Sato
Atushi Nakano
Akemi Kakino
Shunji Ohshima
Tomomasa Kanda
Ryo Yoshimoto
Tatsuya Sawamura
National Cerebral and Cardiovascular Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lectin-like oxidized LDL receptor-1 (LOX-1) is an endothelial receptor for oxidized LDL (oxLDL) and plays multiple roles in the development of cardiovascular diseases. We screened more than 400 foodstuff extracts for identifying materials that inhibit oxLDL binding to LOX-1. Results showed that 52 extracts inhibited LOX-1 by more than 70% in cell-free assays. Subsequent cell-based assays revealed that a variety of foodstuffs known to be rich in procyanidins such as grape seed extracts and apple polyphenols, potently inhibited oxLDL uptake in Chinese hamster ovary (CHO) cells expressing LOX-1. Indeed, purified procyanidins significantly inhibited oxLDL binding to LOX-1 while other ingredients of apple polyphenols did not. Moreover, chronic administration of oligomeric procyanidins suppressed lipid accumulation in vascular wall in hypertensive rats fed with high fat diet. These results suggest that procyanidins are LOX-1 inhibitors and LOX-1 inhibition might be a possible underlying mechanism of the well-known vascular protective effects of red wine, the French Paradox.

Indexed as

Models, BiologicalWineAnimalsBiflavonoidsCatechinCHO CellsCricetinaeCricetulusDrug Evaluation, PreclinicalFlavonoidsFranceHumansLipoproteins, LDLMaleMalusPhenolsBiflavonoidsCatechinFlavonoidsLipoproteins, LDLOLR1 protein, humanoxidized low density lipoproteinPhenolsPolyphenolsProanthocyanidinsprocyanidinScavenger Receptors, Class E

Identifiers

PMID21422743
PMCPMC3066543
OpenAlexW2069116999

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.